- Home
- LICY vs CRDF Comparison
LICY vs CRDF Comparison
Compare LICY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICY
- CRDF
- Stock Information
- Founded
- LICY 2016
- CRDF 1999
- Country
- LICY Canada
- CRDF United States
- Employees
- LICY N/A
- CRDF N/A
- Industry
- LICY Environmental Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LICY Industrials
- CRDF Health Care
- Exchange
- LICY Nasdaq
- CRDF Nasdaq
- Market Cap
- LICY 65.2M
- CRDF 240.2M
- IPO Year
- LICY N/A
- CRDF N/A
- Fundamental
- Price
- LICY $1.52
- CRDF $3.29
- Analyst Decision
- LICY Hold
- CRDF Strong Buy
- Analyst Count
- LICY 2
- CRDF 3
- Target Price
- LICY $4.13
- CRDF $10.33
- AVG Volume (30 Days)
- LICY 1.6M
- CRDF 1.7M
- Earning Date
- LICY 11-07-2024
- CRDF 02-27-2025
- Dividend Yield
- LICY N/A
- CRDF N/A
- EPS Growth
- LICY N/A
- CRDF N/A
- EPS
- LICY N/A
- CRDF N/A
- Revenue
- LICY $27,400,000.00
- CRDF $688,000.00
- Revenue This Year
- LICY $61.64
- CRDF $25.03
- Revenue Next Year
- LICY $21.35
- CRDF N/A
- P/E Ratio
- LICY N/A
- CRDF N/A
- Revenue Growth
- LICY N/A
- CRDF 49.57
- 52 Week Low
- LICY $1.22
- CRDF $1.44
- 52 Week High
- LICY $15.36
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- LICY 39.91
- CRDF 42.10
- Support Level
- LICY $2.15
- CRDF $4.23
- Resistance Level
- LICY $2.52
- CRDF $4.89
- Average True Range (ATR)
- LICY 0.28
- CRDF 0.37
- MACD
- LICY -0.01
- CRDF -0.16
- Stochastic Oscillator
- LICY 8.07
- CRDF 0.62
About LICY Li-Cycle Holdings Corp.
Li-Cycle Holdings Corp is a lithium-ion battery resource recovery and lithium-ion battery recycler. The company's proprietary process Spoke and Hub recycling process is designed at its Spokes, to process battery manufacturing scrap and end-of-life batteries to produce black mass and other intermediate products, and at its Hubs, to process black mass to recover raw materials, including but not limited to lithium carbonate, cobalt sulphate, and nickel sulphate.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").